Patients across Peoria, Glendale, Phoenix, Surprise, Goodyear, and the West Valley trust us because we deliver results with compassion, expertise, and medical excellence
When comparing patients who initiated treatment with exenatide (n=14,076, median follow-up: 969 days), to those starting dulaglutide (n=54,787, median follow-up: 948 days) or liraglutide (n=25,562, median follow-up: 1,007 days), no differences were found in the hazard of composite treatment for diabetic macular edema (DME) and/or proliferative DR: exenatide vs
The antidiabetic effects of ginsenosides may be a result of enhanced GLP1 secretion
Patients are usually trained on self-administration techniques, ensuring they are comfortable and confident in managing their treatment